Apellis Pharmaceuticals (APLS) Stock Price

$17.42 0%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    5

  • Fundamental

    2

  • Technical

    3

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Apellis Pharmaceuticals, AI stock picks, stock alerts and much more.

Sign up

APLS AI Stock Analysis

AI stock analysis for APLS is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Apellis Pharmaceuticals (APLS) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Apellis Pharmaceuticals (APLS) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Apellis Pharmaceuticals (APLS), currently trading at $17.42, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About APLS

LSE

  • Apellis Pharmaceuticals, Inc.

  • Symbol

    APLS

  • Market

    NASDAQ

  • Industry

    Biotechnology

  • Market Cap

    2.2B

Similar Stocks

CPRX Catalyst Pharmaceuticals
CPRX		 $20.95
2.4%
6
INO Inovio Pharmaceuticals
INO		 $1.33
0.00%
3
MRNA Moderna
MRNA		 $29.9
1.9%
3
AVXL Anavex Life Sciences
AVXL		 $9.99
7.4%
6
BBIO BridgeBio Pharma
BBIO		 $43.5
1.1%
7

News

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
July 1, 2025. globenewswire.com
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?

Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?
June 6, 2025. zacks.com
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
June 6, 2025. globenewswire.com
Apellis Pharmaceuticals: Have Some Patience

Apellis Pharmaceuticals: Have Some Patience
May 20, 2025. seekingalpha.com

APLS Alternative Data

Web Traffic

Apellis Pharmaceuticals receives an estimated 25198 monthly visitors to apellis.com.

  • Web Traffic

    25198

  • Change from Previous Month

    24.1%

  • 3 Month Change

    47.6%

  • YoY Change

    47.6%

Twitter Followers

Apellis Pharmaceuticals has 1,643 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.2% over the last month.

  • Twitter Followers

    1643

  • Daily Change

    0%

  • 1 Month Change

    0.2%

  • 3 Month Change

    0.5%

  • YoY Change

    0.5%

Youtube Subscribers

Apellis Pharmaceuticals has 836 subscribers on its main Youtube channel, up by 0.2% over the last month.

  • Youtube Subscribers

    836

  • Daily Change

    0%

  • 1 Month Change

    0.2%

  • 3 Month Change

    0.6%

  • YoY Change

    0.6%

LinkedIn Followers

83,525 are following Apellis Pharmaceuticals on LinkedIn, up by 1.5% over the last month.

  • LinkedIn Followers

    83525

  • Daily Change

    0.1%

  • 1 Month Change

    1.5%

  • 3 Month Change

    4.7%

Job Postings

Apellis Pharmaceuticals currenly has an estimated 21 open job postings, up by 16.7% over the last month.

  • Job Postings

    21

  • Daily Change

    4.5%

  • 1 Month Change

    16.7%

  • 3 Month Change

    51.2%

  • YoY Change

    51.2%

LinkedIn Employees

According to LinkedIn, Apellis Pharmaceuticals has 771 employees, up by 1.4% over the last month.

  • LinkedIn Employees

    771

  • Daily Change

    0%

  • 1 Month Change

    1.4%

  • 3 Month Change

    1.8%

  • YoY Change

    1.8%

Reddit Mentions

Apellis Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Business Outlook

According to employee reviews, the business outlook among employees at Apellis Pharmaceuticals is 43 out of 100 (neutral), up by 4.9% over the last month.

  • Business Outlook

    43

  • Change from Previous Month

    4.9%

  • 3 Month Change

    2.3%

  • YoY Change

    2.3%

News Mentions

Apellis Pharmaceuticals was mentioned 4 times in the news yesterday.

  • News Mentions

    4

  • Daily Change

    33.3%

  • 1 Month Change

    0%

  • 3 Month Change

    300%

App Downloads

  • App Downloads

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

APLS Financials

APLS Key Metrics

  • Total Revenue

    $212.5M

  • Net Income

    -$36.4M

  • Earnings per Share

    -$0.29

  • Free cash flow

    $19.3M

  • EBITDA

    -$24.1M

  • EBITDA Ratio

    -0.113298

  • Total Assets

    $885.1M

APLS 2-year Revenue & Income
APLS 2-year Free Cash Flow

APLS Technicals

APLS SMA
APLS RSI

FAQ

What's the current price of Apellis Pharmaceuticals (APLS) Stock?
The price of an Apellis Pharmaceuticals (APLS) share is $17.42.

What's the market cap of Apellis Pharmaceuticals?
The current market cap of Apellis Pharmaceuticals is 2.2B.

Should I buy or sell APLS?
Apellis Pharmaceuticals shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Apellis Pharmaceuticals is better viewed as a hold or accumulate position while waiting for further developments.

Is Apellis Pharmaceuticals a good investment?
The current analysis of Apellis Pharmaceuticals' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Apellis Pharmaceuticals' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy Apellis Pharmaceuticals (APLS) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Apellis Pharmaceuticals stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to Apellis Pharmaceuticals (APLS) that investors often compare it to?
Apellis Pharmaceuticals (APLS) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.

What is the forecast for Apellis Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Apellis Pharmaceuticals' stock price to be around $16.66 in 2026. Starting from the current price of $17.42, this represents a 4.3% change in price, indicating a bearish outlook for the stock.

How to buy Apellis Pharmaceuticals (APLS) Stock?
Apellis Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Apellis Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.